Cargando…

Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review

Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. Cardiomyopathy and heart failure (HF) are rare but serious complications associated with anagrelide use, although no cases were reported during Japanese Phase I to III studies. A 46-year-old, otherwise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugawara, Masafumi, Okada, Sho, Kanda, Masato, Iseki, Tohru, Sakaida, Emiko, Kobayashi, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683813/ https://www.ncbi.nlm.nih.gov/pubmed/35342135 http://dx.doi.org/10.2169/internalmedicine.9090-21

Ejemplares similares

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016)

Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia
por: Song, David, et al.
Publicado: (2023)

Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
por: Lim, Young-Hyo, et al.
Publicado: (2010)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008)

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
por: Byun, Ja Min, et al.
Publicado: (2022)

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
por: Gotic, Mirjana, et al.
Publicado: (2020)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
por: Birgegård, Gunnar, et al.
Publicado: (2018)

Leg Ulcers Associated with Anagrelide
por: Oskay, Tuba, et al.
Publicado: (2021)

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France
por: Rey, Jérôme, et al.
Publicado: (2014)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study
por: Iwahana, Togo, et al.
Publicado: (2020)

Anagrelide-Induced Supraventricular Tachycardia: A Case Report
por: Badar, Faraz, et al.
Publicado: (2022)

Association between early intensive care or coronary care unit admission and post-discharge performance of activities of daily living in patients with acute decompensated heart failure
por: Kanda, Masato, et al.
Publicado: (2021)

Emerging treatments for essential thrombocythemia
por: Okoli, Steven, et al.
Publicado: (2011)

Thromboembolic complication in Essential Thrombocythemia
por: Mozaheb, Zahra
Publicado: (2012)

Essential thrombocythemia: Busulphan revisited
por: Koduri, Prasad R.
Publicado: (2016)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Essential Thrombocythemia in Children and Adolescents
por: Putti, Maria Caterina, et al.
Publicado: (2021)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report
por: Oda, Yasuhiro, et al.
Publicado: (2019)

Stress Cardiomyopathy Complicated by Left Ventricular Thrombi and Cerebral Infarctions in a Patient with Essential Thrombocythemia
por: Hwang, Seung Hwan, et al.
Publicado: (2011)

Moyamoya syndrome in an adult with essential thrombocythemia
por: Lazzaro, Marc A., et al.
Publicado: (2011)

Essential thrombocythemia: Rare cause of chorea
por: Venkatesan, Eswaradass Prasanna, et al.
Publicado: (2014)

Mutant calreticulin causes essential thrombocythemia
por: Shimoda, Kazuya, et al.
Publicado: (2017)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Essential Thrombocythemia Presenting as Paraneoplastic Glomerulonephritis
por: Abdulla, M. C., et al.
Publicado: (2018)

Patient Perspectives of a Non-Invasive Telemonitoring Tool for Patients with Heart Failure
por: Sano, Motohiro, et al.
Publicado: (2022)

A Bone Marrow Biopsy Is Mandatory for a Diagnosis of Essential Thrombocythemia
por: Kobayashi, Zen
Publicado: (2019)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Cardiac Surgery Using Hypothermic Circulatory Arrest in a Case of Essential Thrombocythemia
por: Enomoto, Masahide, et al.
Publicado: (2018)

Systemic Mastocytosis and Essential Thrombocythemia: Case Report and Literature Overview
por: Cancian, Mauro, et al.
Publicado: (2019)

Cerebral Dissecting Aneurysms in Patients with Essential Thrombocythemia
por: Baek, Jin Wook, et al.
Publicado: (2014)

Essential thrombocythemia: a rare disease in childhood
por: Beatrice, Julia Maimone, et al.
Publicado: (2013)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

Thiol-disulphide Homeostasis in Essential Thrombocythemia Patients
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2019)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Generalized granuloma annulare associated with essential thrombocythemia
por: Polineni, Sai P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_difb95uan9i8d2f9df46opba5l